ArticleiLIVER2026
Salvage robotic associating liver partition and portal vein ligation for staged hepatectomy for advanced hepatocellular carcinoma with insufficient future liver remnant after conversion therapy.
Article in iLIVER, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many cases of hepatocellular carcinoma (HCC) are initially considered unresectable. Advances in conversion therapy have enabled some of these patients to subsequently undergo curative resection. However, an insufficient future liver remnant (FLR) prevents patients with HCC undergoing conversion therapy from obtaining the opportunity for surgical resection. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) has been shown to be effective in promoting FLR hypertrophy in patients with HCC. Nevertheless, the safety and feasibility of ALPPS in patients with HCC who have an insufficient FLR after conversion therapy have rarely been reported. Here, we report the first case in which salvage robotic ALPPS enabled a patient with HCC and insufficient FLR after conversion therapy to undergo radical resection. This 56-year-old man was diagnosed with initially unresectable HCC and received five cycles of lenvatinib plus pembrolizumab. Although a partial response was achieved on oncological evaluation, the patient was not eligible for surgical resection because the FLR remained insufficient at 35.5% of the standard liver volume. To promote FLR hypertrophy and achieve radical resection, we performed a two-stage robotic ALPPS after the fifth cycle of systemic therapy. The FLR increased from 35.5% to 49.4% one month after the first stage of ALPPS (robotic cholecystectomy, right portal vein ligation, and liver partition), and subsequent robotic right hemihepatectomy was successfully performed. The patient recovered uneventfully after the two-stage procedure, and no recurrence was observed at the 3-month postoperative follow-up. This case demonstrates that total robotic ALPPS is a feasible bridge to curative resection for selected patients with insufficient FLR after successful conversion therapy. Building upon the concept of salvage ALPPS, this report further highlights the technical advantages of a total robotic platform in facilitating precise, minimally invasive staged hepatectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.